redefining eARLY sTAGE iNVESTMENTs RESI 3 Early Stage Life Science Investment Just Hit a Home Run! ONSITE GUIDE September 17, 2014 Fenway Park Boston, MA RESIConference.com #RESI3 LifeScienceNation.com EMC Level FENWAY PARK EMC CLUB 3 LEVEL 3 EMC2 SUITE L2 Exit FIELD VIEW Board Room Exit Exit Stairs/Escalators workshopS TO State st. Bar Area pavilion LEVEL PARTNERING Forum REGISTRATION sTATE sTREET PAVILION Level State Street. PAVILION lEVEL 4 FENWAY PARK pRESS ROOM mEDIA dINING TRACK 2 TRACK 1 Exit 13 1 2 12 1 FIELD VIEW 2 12 3 Exit Exit 11 11 3 4 10 10 4 5 5 6 6 7 7 8 9 9 8 15 25 16 25 16 26 32 17 30 17 26 27 28 29 30 31 18 24 27 28 29 18 Stairs/Escalators 24 19 23 23 22 22 21 21 20 20 19 13 14 14 15 Bar Area PANELS Exhibiting companies TO EMC LEVEL pRESENTING companies contents TABLE OF CONTENTS Welcome from Dennis Ford - - - - - - - 2 RESI Schedule - - - - - - 3 Investor Panels - - - - - - - 5 Early Stage Workshops - - - - - - 25 Partnering Forum - - - - - - - 26 RESI Innovation Challenge - - - - - - - 27 Exhibiting Companies - - - - - - 29 Sponsors - - - - - - - 30 Media Partners - - - - - - - 33 1 welcome to resi Life Science Nation would like to welcome you to the third Redening Early Stage Investments (RESI) conference. We're excited to see you here at our new landmark location, Fenway Park. I hope you are ready to get the most out of a day lled with content, meetings and opportunities for everyone who has a stake in the early-stage life science sector. While the venue and much of our cutting-edge content may be new, our all-day partnering sessions remain the core of RESI. Face-to-face meetings between entrepreneurs and investors are the most vital part of the fundraising process, and RESI is designed to make that direct contact as productive and as meaningful as possible. The relationships you start at RESI could make your company. Throughout the day we have two tracks of discussion panels, where you can hear from leaders who represent the diversity of the life science investment world today. We also invite you to join our RESI workshops, where you will receive hands-on tactical advice about many aspects of the process of taking your technology towards commercialization. We'd also like to bring your attention to the RESI Innovation Challenge taking place today. To be a part of this virtual investment challenge, meet with the RESI Innovators showcasing their groundbreaking technologies throughout the exhibition hall, and put your 'RESI Cash' toward those that most inspire you. Finally, we'd like to thank you for being here today. Whether you're here today as an early-stage investor or as an entrepreneur developing a breakthrough life science technology, you are a vital part of the RESI community and we're honored that you've made RESI part of your journey from discovery to commercialization. Sincerely, Dennis Ford Founder & CEO Life Science Nation 2 RESI SCHEDULE Track 1: Track 2: Track 3: Track 4: Investor Investor Early Stage Partnering Panels Panels Workshops Forum Media Dining Press Room Suite L2 EMC CLUB 7:00 - 8:00 AM: Registration & Breakfast 8:00 - Point-of-Care aNGEL 8:50 Institution gROUP AM 9:00 - VENTURE PATIENT MORNING 9:50 PHILANTHROPY GROUPS fundraising EARLY STAGE AM bootcamp PARTNERING 10:00 FORUM mEDICAL device - boston 10:50 Strategics AM multi- and single innovation capital family 11:00 offices - Orphan/rare 11:50 disease AM 12:00 - 1:00 PM: Break for Lunch 1:00 - cro OUTBOUND 1:50 direct investment FUNDRAISING THE LIFE SCIENCES PM LEGAL LANDSCAPE 2:00 - bIG NON-PROFIT AFTERNOON 2:50 PHARMA DIRECT INVESTMENT branding & EARLY STAGE PM messaging PARTNERING 3:00 FORUM - VIRTUAL FUNDRAISING 3:50 PHARMA PARTNERS PM 4:00 - CORPORATE vENTURE 4:50 VENTURE CAPITAL CAPITAL PM 5:00 - 7:00 PM: Cocktail Reception State Street Pavilion 3 investor panels Track 1 Track 1 Moderator & Panelists 8:00 - 8:50 AM • Monique Yoakim-Turk, Partner, Technology Development Fund of Boston Children’s Hospital M • Barbara Gamez Sims, Technology Licensing Manager, Mayo Clinic Ventures Point-of-Care • Chris Coburn, VP, Innovation, Partners HealthCare Institution • Kanad Das, Program Manager, Stanford SPARK • Manu Nair, Vice President, Technology Ventures, Oklahoma Medical Research Foundation 9:00 - 9:50 AM • Brian Horsburg, Trustee, NeuroNetworks Fund M • Albert Roy, CEO, Lupus Therapeutics VENTURE • Charlotte Hubbert, Venture Investor, Bill & Melinda Gates Foundation PHILANTHROPY • Daniel Auclair, VP of Translational Research, Multiple Myeloma Research Foundation • Tim Armour, President & CEO, Cure Alzheimer's Fund 10:00 - 10:50 AM • Yuri Haverman, Strategic Innovation, Medical Surgical Systems, Becton Dickinson M • Aaron Sandoski, Co-Founder & Managing Director, Norwich Ventures mEDICAL device • Josh Phillips, Managing Partner, Catalyst Health Ventures Strategics • Juan Carlos Serna, Vice President, HPA Ventures • Lawrence Cho, Senior Director of Corporate Strategy & Business Development, Medtronic 11:00 - 11:50 AM • Peter Saltonstall, President & CEO, The National Organization for Rare Diseases M • Brian Malkin, Partner, McGuireWoods Orphan/rare • Chris Adams, CEO, Cydan • Jean-Marc Quach, Executive Director, The Alpha-1 Project disease • Mark Barrett, VP, Head Strategy & BD, Rare Diseases, Genzyme • Mark Day, Senior Director, Strategic Evaluation, Alexion 1:00 - 1:50 PM • Peter Lee-Armandt, Manager, Life Sciences Advisory, Sathguru M • David Gee, Vice President, Business Development, Cato BioVentures cro direct • Joseph Vacca, Senior Vice President, Early Success Sharing Partnerships, WuXi AppTec investment • Krishna Kodukula, Executive Director, Strategic Development, SRI International • Michael Recny, CEO, Calvert Holdings 2:00 - 2:50 PM • Bill Kohlbrenner, Chief Science Ofcer, Boston Innovation Capital M • Donnie McGrath, VP, Business Development, Bristol-Myers Squibb bIG • Florian Puehler, Alliance Manager, Bayer HealthCare PHARMA • Kara Bortone, Head of Company Sourcing, Janssen Labs, Johnson & Johnson • Richard Brudnick, SVP Corporate Development, Biogen Idec 3:00 - 3:50 PM • Gene Williams, Founder, Virtua M • Andrew Perlman, Managing Director & CMO, Velocity Pharmaceutical Development VIRTUAL • Baiju Shah, CEO, BioMotiv PHARMA • Dennis Goldberg, President, Benu Biopharma • Jarrod Longcor, CBO, Avillion 4:00 - 4:50 PM • Vikas Goyal, Senior Associate, SR One M • Jason Haer, Director of Investments, Sano-Genzyme BioVentures CORPORATE • Marian Nakada, Vice President, Venture Investments, Johnson & Johnson Development Corporation • Mette Agger, Managing Partner, Lundbeckfond Ventures VENTURE CAPITAL • Stephen R. Padgette, Vice President, R&D Research Strategy, Monsanto Company • Tetsuro Iwata, Senior Manager, MP Healthcare Venture Management 5 investor panels Track 2 Track 2 Moderator & Panelists 8:00 - 8:50 AM • Barbara Nelsen, Founder & CEO, Nelsen Biomedical M • Bill Whitaker, Managing Director, Co-Chair Life Science Section, Golden Seeds aNGEL • Brian Frenzel, Member, Band of Angels gROUP • Praveen Tailam, Managing Director, TiE Angels Boston • Stephen M. Nagler, Executive Director, MedPro Investors 9:00 - 9:50 AM • Steve Perrin, CEO & CSO, ALS Therapy Development Institute M • Annette Bakker, President & CSO, Children's Tumor Foundation PATIENT • Joe Camaratta American Heart Association • Monica Gow, Executive Director, Wake Up Narcolepsy GROUPS • Steven Young, President & COO, Addario Lung Cancer Medical Institute 10:00 - 11:30 AM • Bill Brah, Founder & Executive Director, UMass Venture Development Center M • Alejandra Paredones, CEO & Founder, BSI Capital Group multi- • Christopher de Souza, Director, Broadview Ventures and • Melissa Krauth, Principal, Claria Bioscience single • Meredith Fisher, Director & Partner Investments, family • Todd Holmes, Director, Gurnet Point Capital offices 1:00 - 1:50 PM • Rick Berenson, CEO, Thermalin Diabetes M • Fred Colen, President & CEO, BeneChill OUTBOUND • Gabor Bethlendy, CCO & Founder, Parabase Genomics FUNDRAISING • Michael Tippie, CEO, TomegaVax • Richard Gauthier, Head of Business Development, Microbiotix 2:00 - 2:50 PM • David Sandak, Vice President, Strategy & Research, Accelerate Brain Cancer Cure M • Benjamin Seckler, Founder & President, Charley's Fund NON-PROFIT • Howard Fillit, Executive Director & CSO, Alzheimer's Drug Discovery Foundation DIRECT INVESTMENT • Keting Chu, VP, Research TAP, The Leukemia & Lymphoma Society • Salvatore La Rosa, Senior Director of Research and Development, Children's Tumor Foundation 3:00 - 3:50 PM • Colin Widen, CEO, Boston Innovation Capital M • Adam Cutler, Managing Director, Trout Group FUNDRAISING • Dan Ross, CEO, IMS Health Capital PARTNERS • John Cullity, Partner, Torreya Partners • Paul Papi, Director, Investment Banking, Freedom Investors Corporation 4:00 - 4:50 PM • Bernadette Adamo, Director, Northeast Healthcare/Life Sciences, Silicon Valley Bank M • Jayson Punwani, Associate, Pappas Ventures vENTURE • Jerel Davis, Operating Partner, Versant Ventures CAPITAL • Kiran Reddy, Associate Partner, Third Rock Ventures • Tom Needham, Managing Director, Synthesis Capital 7 McGuireWoods LLP is proud to sponsor Life Science Nation and the 2014 Redefining Early Stage Investments Conference Our commitment to providing clients with quality work and personalized service has allowed us to become a This commitment includes delivering exceptional value, using technology to provide effective legal solutions and employing a diverse workforce to bring real world and innovative perspectives to our life sciences clients. Brian J. Malkin, Senior